Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5049754 | 0.98 | TSHR (0.42) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL30179205 | 0.98 | TSHR (0.42) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL15360069 | 0.98 | TSHR (0.42) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL31672720 | 0.98 | TSHR (0.42) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL16917910 | 0.98 | TSHR (0.42) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL6463788 | 0.92 | TSHR (0.50) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL7648165 | 0.90 | TSHR (0.48) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL4405371 | 0.85 | ALDH1A1 (0.35) | TSHRNAMPTALDH1A1TDP1CA2 | |
| SCHEMBL9275566 | 0.83 | TSHR (0.41) | TSHRHSD17B10NAMPTALDH1A1TDP1 | |
| SCHEMBL28565203 | 0.83 | CA2 (0.35) | TSHRNAMPTALDH1A1TDP1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6350795-B1 | ACOUSTIC PHASE-CHANGE CONDUCTIVE INK CONTAINING LOW MOLECULAR WEIGHT OXYALKYLENE SEGMENTS COMPLEXED WITH UREA DERIVATIVES | XEROX CORPORATION | 2002-02-26 | — | — | US | claimed |
| US-6096125-A | Ink compositions | XEROX CORPORATION (US) | 2000-08-01 | — | — | US | claimed |
| US-5700316-A | COMPRISED OF COLORANT AND VEHICLE OF POLY(ALKYLENE OXIDE) ALKYLATE OR DIALKYLATE OR POLYOXA-ALKANOIC ESTER OR DIESTER | XEROX CORPORATION (US) | 1997-12-23 | — | — | US | claimed |
| EP-2427186-B1 | DIHYDROOROTATE-DEHYDROGENASEE INHIBITORS AS VIROSTATIC COMPOUNDS | PANOPTES PHARMA GES M B H (AT) | 2022-01-12 | — | — | EP | disclosed |
| US-20170073468-A1 | METHOD FOR PREPARING FUNCTIONALIZED POLYMERS FROM POLYMER ALCOHOLS | NEKTAR THERAPEUTICS | 2017-03-16 | — | — | US | disclosed |
| EP-3093284-A1 | ETHEREAL OXYGEN-CONTAINING PERFLUOROALKYL GROUP-SUBSTITUTED PYRAZOLE COMPOUND AND PRODUCTION METHOD THEREFOR | Asahi Glass Company, Limited (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-20160295864-A1 | ETHEREAL OXYGEN ATOM-CONTAINING PERFLUOROALKYL GROUP-SUBSTITUTED PYRAZOLE RING COMPOUND AND METHOD FOR ITS PRODUCTION | ASAHI GLASS COMPANY, LIMITED (JP) | 2016-10-13 | — | — | US | disclosed |
| US-20140073802-A1 | MALEIMIDYL POLYMER DERIVATIVES | NEKTAR THERAPEUTICS (US) | 2014-03-13 | — | — | US | disclosed |
| US-8354433-B2 | Anti-inflammatory agents as virostatic compounds | 4SC AG (DE) | 2013-01-15 | — | — | US | disclosed |
| US-20120028985-A1 | COMBINATIONAL THERAPY FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2012-02-02 | — | — | US | disclosed |
| EP-2362771-A1 | COMBINATIONAL THERAPY COMPRISING DHODH INHIBITOR AND METHOTREXATE FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2011-09-07 | — | — | EP | disclosed |
| US-6350795-B1 | ACOUSTIC PHASE-CHANGE CONDUCTIVE INK CONTAINING LOW MOLECULAR WEIGHT OXYALKYLENE SEGMENTS COMPLEXED WITH UREA DERIVATIVES | XEROX CORPORATION | 2002-02-26 | — | — | US | disclosed |
| EP-1095006-A1 | DERIVATIVES OF 1-OXYL-4-HYDROXY-OR 4-AMINO-2,2,6,6-TETRAMETHYLPIPERIDINE AS POLYMERIZATION INHIBITORS FOR (METH) ACRYLATE MONOMERS | Ciba SC Holding AG (CH) | 2001-05-02 | — | — | EP | disclosed |
| US-6096125-A | Ink compositions | XEROX CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
| US-6080864-A | A STABILIZER PREVENTING THE PREMATURE POLYMERIZATION OF ACRYLIC AND METHACRYLIC ACIDS, THEIR ESTERS, THEIR AMIDES, VINYL ACETATE AND ACRYLONITRILE IN THE PRESENCE OF WATER | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2000-06-27 | — | — | US | disclosed |
| EP-1000032-A1 | INHIBITION OF PULP AND PAPER YELLOWING USING NITROXIDES AND OTHER COADDITIVES | Ciba SC Holding AG (CH) | 2000-05-17 | — | — | EP | disclosed |
| WO-2000003965-A1 | DERIVATIVES OF 1-OXYL-4-HYDROXY- OR 4-AMINO-2,2,6,6-TETRAMETHYLPIPERIDINE AS POLYMERIZATION INHIBITORS FOR (METH)ACRYLATE MONOMERS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2000-01-27 | — | — | WO | disclosed |
| US-5932735-A | STABILIZERS | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1999-08-03 | — | — | US | disclosed |
| WO-1999005108-A1 | INHIBITION OF PULP AND PAPER YELLOWING USING NITROXIDES AND OTHER COADDITIVES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 1999-02-04 | — | — | WO | disclosed |
| US-5700316-A | COMPRISED OF COLORANT AND VEHICLE OF POLY(ALKYLENE OXIDE) ALKYLATE OR DIALKYLATE OR POLYOXA-ALKANOIC ESTER OR DIESTER | XEROX CORPORATION (US) | 1997-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160295864-A1 | ETHEREAL OXYGEN ATOM-CONTAINING PERFLUOROALKYL GROUP-SUBSTITUTED PYRAZOLE RING COMPOUND AND METHOD FOR ITS PRODUCTION | CYP2F1, CYP2E1, CYP2C19 | TSHR 270/4885HSD17B10 717/4885MGAM 4132/4885 |
| US-20120028985-A1 | COMBINATIONAL THERAPY FOR TREATING AUTOIMMUNE DISEASE | HLA-DRB1, IL2, SSB | TSHR 1542/4885HSD17B10 2061/4885MGAM 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.